tiprankstipranks
Advertisement
Advertisement

ALKS Stock Latest News

Needham Reiterates Buy Rating on Alkermes as Preclinical ALKS 7290 Data Support Unchanged $50 Price Target
RatingsNeedham Reiterates Buy Rating on Alkermes as Preclinical ALKS 7290 Data Support Unchanged $50 Price Target
5d ago
ALKS
Alkermes Shareholders Approve Amended Stock Incentive Plan
PremiumCompany Announcements
Alkermes Shareholders Approve Amended Stock Incentive Plan
13d ago
8K
ALKS
Alkermes’ Earnings Call Highlights Growth and LUMRYZ Surge
PremiumCompany Announcements
Alkermes’ Earnings Call Highlights Growth and LUMRYZ Surge
14d ago
ALKS
Alkermes Advances Phase 3 Narcolepsy Study With ALKS 2680, Adding a New Catalyst to Its Pipeline
PremiumCompany Announcements
Alkermes Advances Phase 3 Narcolepsy Study With ALKS 2680, Adding a New Catalyst to Its Pipeline
18d ago
ALKS
Alkermes price target raised to $48 from $45 at Baird
PremiumThe Fly
Alkermes price target raised to $48 from $45 at Baird
20d ago
ALKS
Alkermes announces ‘positive’ topline results from REVITALYZ Phase 3 study
PremiumThe FlyAlkermes announces ‘positive’ topline results from REVITALYZ Phase 3 study
21d ago
ALKS
Alkermes Reports Positive Phase 3 Results for LUMRYZ
Premium
Company Announcements
Alkermes Reports Positive Phase 3 Results for LUMRYZ
21d ago
8K
ALKS
Alkermes Advances Brilliance NT2 Phase 3 Trial, Raising Interest in Narcolepsy Market
Premium
Company Announcements
Alkermes Advances Brilliance NT2 Phase 3 Trial, Raising Interest in Narcolepsy Market
26d ago
ALKS
Alkermes price target raised to $48 from $42 at UBS
PremiumThe Fly
Alkermes price target raised to $48 from $42 at UBS
27d ago
ALKS
Alkermes price target raised to $50 from $45 at Needham
PremiumThe Fly
Alkermes price target raised to $50 from $45 at Needham
27d ago
LLY
ALKS
Alkermes Earnings Call: LUMRYZ Momentum Drives Growth
PremiumCompany Announcements
Alkermes Earnings Call: LUMRYZ Momentum Drives Growth
28d ago
ALKS
Alkermes reports Q1 EPS (40c) vs 13c last year
PremiumThe Fly
Alkermes reports Q1 EPS (40c) vs 13c last year
28d ago
ALKS
Alkermes sees FY26 revenue $1.73B-$1.84B, consensus $1.8B
PremiumThe FlyAlkermes sees FY26 revenue $1.73B-$1.84B, consensus $1.8B
28d ago
ALKS
Alkermes plc (ALKS) Q1 Earnings Cheat Sheet
Premium
Pre-Earnings
Alkermes plc (ALKS) Q1 Earnings Cheat Sheet
1M ago
ALKS
Alkermes: Positive Alixorexton Phase 2 Data in Narcolepsy Type 1 Support Advancement to Phase 3 and Reinforce Buy Rating
Premium
Ratings
Alkermes: Positive Alixorexton Phase 2 Data in Narcolepsy Type 1 Support Advancement to Phase 3 and Reinforce Buy Rating
2M ago
ALKS
Alkermes to present additional data from Vibrance-1 Phase 2 alixorexton study
PremiumThe Fly
Alkermes to present additional data from Vibrance-1 Phase 2 alixorexton study
2M ago
ALKS
Alkermes announces publication of 56-week post hoc analysis of Lybalvi
PremiumThe Fly
Alkermes announces publication of 56-week post hoc analysis of Lybalvi
2M ago
ALKS
Alkermes price target raised to $36 from $34 at BofA
PremiumThe Fly
Alkermes price target raised to $36 from $34 at BofA
2M ago
ALKS
Alkermes price target lowered to $44 from $45 at RBC Capital
PremiumThe Fly
Alkermes price target lowered to $44 from $45 at RBC Capital
2M ago
ALKS
Alkermes management to meet with Piper Sandler
PremiumThe FlyAlkermes management to meet with Piper Sandler
2M ago
ALKS
Alkermes announces initiation of Brilliance Studies
Premium
The Fly
Alkermes announces initiation of Brilliance Studies
2M ago
ALKS
Alkermes jumps 15% on renewed biotech M&A buzz, says Leerink
Premium
The Fly
Alkermes jumps 15% on renewed biotech M&A buzz, says Leerink
2M ago
LLY
ALKS

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >